Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Head and Neck Cancer

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 141 articles:
HTML format

Single Articles

    December 2022
  1. KUSAKA T, Shiga K, Katagiri K, Saito D, et al
    Treatment Outcomes and Prognostic Factors of Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and Fluorouracil in Advanced Head and Neck Cancer.
    Anticancer Res. 2022;42:6047-6056.
    PubMed     Abstract available

  2. INAGAKI T, Sato M, Kin M, Otsuka K, et al
    Predictive Factors of Febrile Neutropenia After Primary Prophylactic Pegfilgrastim With DCF Chemotherapy for Esophageal Cancer.
    Anticancer Res. 2022;42:6071-6081.
    PubMed     Abstract available

  3. HAMAI Y, Emi M, Ibuki Y, Kurokawa T, et al
    Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery.
    Anticancer Res. 2022;42:6037-6045.
    PubMed     Abstract available

  4. KOUZU K, Tsujimoto H, Uehata N, Ishibashi Y, et al
    Modified Geriatric Nutrition Risk Index as a Prognostic Predictor for Unresectable/Recurrent Esophageal Cancer.
    Anticancer Res. 2022;42:5999-6006.
    PubMed     Abstract available

  5. MORISHITA Y, Takenouchi K, Sakashita S, Matsuura K, et al
    Immunohistochemical Analysis of Common Cancer Antigens in Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5751-5761.
    PubMed     Abstract available

  6. MOTOYAMA S, Hosaka M, Kamei T, Ueno M, et al
    A Multi-institutional Study to Diagnose the Risk of Lymph Node Metastasis Using a CRP Genetic Polymorphism Test Kit in pT1, cN0 Thoracic Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:6105-6112.
    PubMed     Abstract available

    November 2022
  7. KING K, Rauch R, Roy S, Menyok O, et al
    Impact of Routine Surveillance Imaging on Recurrence in Sinonasal Malignancies.
    Anticancer Res. 2022;42:5449-5455.
    PubMed     Abstract available

  8. AOYAMA T, Maezawa Y, Hara K, Ju M, et al
    The Clinical Impact of Other Primary Cancer in Patients Who Received Curative Treatment for Esophageal Cancer.
    Anticancer Res. 2022;42:5635-5641.
    PubMed     Abstract available

  9. SATO H, Nishikawa K, Hamakawa T, Kusunoki C, et al
    Evaluating Neoadjuvant Chemotherapy for Lower Esophageal Squamous Cell Carcinoma by Measuring Esophageal Wall Thickness.
    Anticancer Res. 2022;42:5655-5662.
    PubMed     Abstract available

  10. CHO JS, Kim HK
    Thyroglobulin Levels as a Predictor of Papillary Cancer Recurrence After Thyroid Lobectomy.
    Anticancer Res. 2022;42:5619-5627.
    PubMed     Abstract available

  11. REUTER I, Muller HH, Wiegand S
    Prognostic Significance of the Nodal Ratio and Number of Positive Nodes in Patients With Squamous Cell Carcinomas of the Head and Neck.
    Anticancer Res. 2022;42:5567-5570.
    PubMed     Abstract available

  12. KYLMA AK, Sorsa T, Jouhi L, Mustonen HK, et al
    Prognostic Role of Porphyromonas gingivalis Gingipain Rgp and Matrix Metalloproteinase 9 in Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:5415-5430.
    PubMed     Abstract available

  13. SU PH, Hsu CC, Hsueh SW, Hung CY, et al
    Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
    Anticancer Res. 2022;42:5609-5618.
    PubMed     Abstract available

  14. LANDSTROM F, Reizenstein J, Kristiansson S
    Detection of Recurrence After Primary Treatment for Oropharyngeal Carcinoma.
    Anticancer Res. 2022;42:5597-5600.
    PubMed     Abstract available

    October 2022
  15. OKADA T, Matsuki T, Fushimi C, Okamoto I, et al
    Nivolumab for Platinum-refractory and -sensitive Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:4907-4912.
    PubMed     Abstract available

  16. SAKAI M, Sohda M, Uchida S, Yamaguchi A, et al
    Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) for Patients With Potentially Resectable Esophageal Cancer.
    Anticancer Res. 2022;42:4929-4935.
    PubMed     Abstract available

    September 2022
  17. MILAS ZL, Neelands B, Trufan SJ, Benbow J, et al
    Survivorship Care Plans Improve the Identification of Post-radiation Hypothyroidism After Head and Neck Cancer Treatment.
    Anticancer Res. 2022;42:4429-4437.
    PubMed     Abstract available

  18. SANO D, Tokuhisa M, Takahashi H, Hatano T, et al
    Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
    Anticancer Res. 2022;42:4477-4484.
    PubMed     Abstract available

  19. TSUZUKI H, Suzuki H, Tamaki T, Sone M, et al
    Detection Ability of (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Clinical T Classification of Synchronous Esophageal Cancer in Pharyngeal Cancer.
    Anticancer Res. 2022;42:4597-4602.
    PubMed     Abstract available

  20. RADES D, Kopelke S, Schild SE, Tvilsted S, et al
    Sleep Problems Prior to Radio-chemotherapy in Patients With Locally Advanced Cancer of the Esophagus or the Esophagogastric Junction.
    Anticancer Res. 2022;42:4529-4533.
    PubMed     Abstract available

  21. YODA M, Sakuma K, Kii T, Tanaka A, et al
    Study of the Acquisition of Sensitivity to Paclitaxel Plus Cetuximab by the Addition of Low-dose Proteasome Inhibitor.
    Anticancer Res. 2022;42:4273-4283.
    PubMed     Abstract available

  22. YASUI K, Kondou R, Miyata H, Iizuka A, et al
    Immunological and Genetic Characterization of Patients With Head and Neck Cancer who Developed Recurrence.
    Anticancer Res. 2022;42:4417-4428.
    PubMed     Abstract available

  23. SAKUMA K, Kii T, Takahashi H, Suzuki S, et al
    An In Vivo Study of Local Administration of Low-dose Anti-PD-1 Antibody Using an Oral Cancer Cell Line.
    Anticancer Res. 2022;42:4293-4303.
    PubMed     Abstract available

  24. PAN SH, Chien WC, He JL, Shih LC, et al
    The Contribution of Flap Endonuclease 1 Genotypes to Oral Cancer Risk.
    Anticancer Res. 2022;42:4329-4335.
    PubMed     Abstract available

    August 2022
  25. SASAKI K, Tsuruda Y, Shimonosono M, Noda M, et al
    Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:3905-3911.
    PubMed     Abstract available

  26. SHIMONOSONO M, Sasaki K, Tsuruda Y, Noda M, et al
    Clinical Outcome After Esophagectomy or Definitive Chemoradiotherapy in Elderly Patients (>/=80 Years) With Esophageal Cancer.
    Anticancer Res. 2022;42:3953-3961.
    PubMed     Abstract available

  27. SMILE TD, Reddy CA, Matia B, Fleming CW, et al
    A Reappraisal of Definitive Chemoradiotherapy for Older Adults With Advanced Head and Neck Cancer.
    Anticancer Res. 2022;42:3845-3852.
    PubMed     Abstract available

  28. YOSHII H, Sekihara K, Ideta Y, Nakajima S, et al
    The Expression of SIRT6 Is Associated With Treatment Outcome in Elder Patients With Oral Cancer.
    Anticancer Res. 2022;42:3815-3823.
    PubMed     Abstract available

  29. FANG F, Zhang QI, Pinto-Cuberos JM, Lai J, et al
    Metastatic SMARCB1 Deficient Skin Carcinoma With Neuroendocrine Differentiation in the Parotid Glands Clinically Mimicking Primary Salivary Gland Malignancy: Unusual Case With Diagnostic Pitfalls.
    Anticancer Res. 2022;42:3971-3974.
    PubMed     Abstract available

    July 2022
  30. RADES D, Warwas B, Cremers F, Gerull K, et al
    Impact of Dose-Volume Parameters of Parotid Glands on Xerostomia in Patients Irradiated for Head-and-Neck Cancer.
    Anticancer Res. 2022;42:3551-3556.
    PubMed     Abstract available

  31. KAJIYAMA T, Serada S, Fujimoto M, Ohkawara T, et al
    SOCS1 Gene Therapy for Head and Neck Cancers: An Experimental Study.
    Anticancer Res. 2022;42:3361-3372.
    PubMed     Abstract available

  32. CHEN YK, Ngoc NTM, Chang HW, Su YF, et al
    Chlorogenic Acid Inhibition of Esophageal Squamous Cell Carcinoma Metastasis via EGFR/p-Akt/Snail Signaling Pathways.
    Anticancer Res. 2022;42:3389-3402.
    PubMed     Abstract available

  33. HUBER L, Birk R, Knuettel M, Rotter N, et al
    Targeted Treatment of HPV16-positive and -negative SCC Cells With Small Molecule Tyrosine Kinase Inhibitors and Everolimus Affects MMP2 and MMP14 Expression.
    Anticancer Res. 2022;42:3403-3411.
    PubMed     Abstract available

  34. PRATHAPHAN P, Reamtong O, Ngaokrajang U, Janvilisri T, et al
    Comparative Proteomic Profiling of Cisplatin-resistant Nasopharyngeal Carcinoma Cell Lines: Novel Biomarkers for Improving Chemotherapy of NPC.
    Anticancer Res. 2022;42:3507-3522.
    PubMed     Abstract available

  35. NAKAJIMA M, Muroi H, Kikuchi M, Kubo T, et al
    Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
    Anticancer Res. 2022;42:3725-3733.
    PubMed     Abstract available

  36. NAKANO T, Yasumatsu R, Hashimoto K, Kuga R, et al
    Real-world Experience With Pembrolizumab for Advanced-stage Head and Neck Cancer Patients: A Retrospective, Multicenter Study.
    Anticancer Res. 2022;42:3653-3664.
    PubMed     Abstract available

  37. WEIDLE UH, Nopora A
    Long Non-coding RNAs Sponging MicroRNAs With Efficacy in Preclinical In Vivo Models of Esophageal Squamous Cell Cancer.
    Anticancer Res. 2022;42:3233-3249.
    PubMed     Abstract available

    June 2022
  38. DAVAKIS S, Kapelouzou A, Liakakos T, Mpoura M, et al
    The Role of Toll-like Receptors in Esophageal Cancer.
    Anticancer Res. 2022;42:2813-2818.
    PubMed     Abstract available

  39. TAKAHASHI K, Nishikawa K, Tanishima Y, Ishikawa Y, et al
    Risk Stratification of Postoperative Pneumonia in Patients Undergoing Subtotal Esophagectomy for Esophageal Cancer.
    Anticancer Res. 2022;42:3023-3028.
    PubMed     Abstract available

  40. BOOKA E, Kikuchi H, Haneda R, Soneda W, et al
    Neutrophil-to-Lymphocyte Ratio to Predict the Efficacy of Immune Checkpoint Inhibitor in Upper Gastrointestinal Cancer.
    Anticancer Res. 2022;42:2977-2987.
    PubMed     Abstract available

  41. RADES D, Warwas B, Cremers F, Gerull K, et al
    The First Prognostic Tool to Estimate the Risk of Late Grade >/=3 Xerostomia in Patients Irradiated for Head-and-Neck Cancer.
    Anticancer Res. 2022;42:3035-3039.
    PubMed     Abstract available

  42. ITO K, Ishida H, Fujishima F, Nakamura Y, et al
    Murine Double Minute 2 Antagonist Nutlin-3 Enhanced Chemosensitivity in Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2875-2882.
    PubMed     Abstract available

  43. MATSUKI T, Fushimi C, Miyamoto S, Takahashi H, et al
    Preoperative S-1 Therapy for Head and Neck Carcinoma During the Waiting Period Before Surgery.
    Anticancer Res. 2022;42:3177-3183.
    PubMed     Abstract available

  44. MUSIO D, DE Vincentiis M, D'Urso P, Musacchio A, et al
    Hearing Loss After Cisplatin-based Chemoradiotherapy for Locally Advanced Head and Neck Cancer: A Prospective Single-institution Study.
    Anticancer Res. 2022;42:3003-3009.
    PubMed     Abstract available

  45. ENDO M, Nishioka T, Numazaki K, Hasegawa H, et al
    Reactivation of p53 by RITA Induces Apoptosis in Human Oral Squamous Cell Carcinoma Cells.
    Anticancer Res. 2022;42:2931-2937.
    PubMed     Abstract available

    May 2022
  46. SUOJANEN J, Kainulainen S, Tarvainen L, Tornwall J, et al
    Handgrip Strength Predicts Poorly the Surgical Outcome or Length of Hospitalization in Patients With Surgically Operated Oral Cancer.
    Anticancer Res. 2022;42:2771-2774.
    PubMed     Abstract available

  47. OKAMOTO K, Ninomiya I, Saito H, Shimada M, et al
    Usefulness of Prophylactic Administration of Pegfilgrastim for Esophageal Cancer Chemotherapy: A Single-center Retrospective Study.
    Anticancer Res. 2022;42:2783-2790.
    PubMed     Abstract available

  48. EMI M, Hmai Y, Yoshikawa T, Hirohata R, et al
    Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2791-2795.
    PubMed     Abstract available

  49. KUNTE S, Sharett J, Wei W, Nasr C, et al
    Poorly Differentiated Thyroid Carcinoma: Single Institution Series of Outcomes.
    Anticancer Res. 2022;42:2531-2539.
    PubMed     Abstract available

  50. WARWAS B, Cremers F, Gerull K, Leichtle A, et al
    Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers.
    Anticancer Res. 2022;42:2657-2663.
    PubMed     Abstract available

  51. KATO T, Oshikiri T, Goto H, Sawada R, et al
    Impact of the Platelet-to-Lymphocyte Ratio as a Biomarker for Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2775-2782.
    PubMed     Abstract available

  52. ACHILLA C, Papavramidis T, Angelis L, Chatzikyriakidou A, et al
    The Implication of X-Linked Genetic Polymorphisms in Susceptibility and Sexual Dimorphism of Cancer.
    Anticancer Res. 2022;42:2261-2276.
    PubMed     Abstract available

  53. DOLL C, Steffen C, Beck-Broichsitter B, Richter M, et al
    The Prognostic Significance of p16 and its Role as a Surrogate Marker for Human Papilloma Virus in Oral Squamous Cell Carcinoma: An Analysis of 281 Cases.
    Anticancer Res. 2022;42:2405-2413.
    PubMed     Abstract available

  54. KAJIKAWA H, Hirata M, Haruna M, Ueyama A, et al
    Tumor-infiltrating ICOS(+) Effector Regulatory T-Cells in Oral Squamous Cell Carcinoma as a Promising Biomarker for Prognosis and 'Hot' Tumor.
    Anticancer Res. 2022;42:2383-2393.
    PubMed     Abstract available

  55. AOYAMA T, Ju M, Komori K, Tamagawa H, et al
    The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment.
    Anticancer Res. 2022;42:2711-2717.
    PubMed     Abstract available

  56. WONGPANUWICH W, Yodsanga S, Chaisuparat R, Amornphimoltham P, et al
    Association Between PD-L1 and Histatin1, 3 Expression in Advanced Head and Neck Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2689-2699.
    PubMed     Abstract available

  57. KLIMAITE R, Kazokaite M, Kondrotiene A, Dauksiene D, et al
    Diagnostic Value of Circulating Cell-free DNA in Patients With Papillary Thyroid Cancer.
    Anticancer Res. 2022;42:2289-2299.
    PubMed     Abstract available

  58. HUANG TS, Lee JJ, Huang SY, Cheng SP, et al
    Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells.
    Anticancer Res. 2022;42:2487-2493.
    PubMed     Abstract available

    April 2022
  59. TAKAKUSAGI Y, Kano K, Shima S, Tsuchida K, et al
    Clinical Outcomes of Radiotherapy in Elderly and Younger Patients With T4 Esophageal Cancer: A Retrospective Single-center Analysis.
    Anticancer Res. 2022;42:2095-2104.
    PubMed     Abstract available

  60. REMSCHMIDT B, Pau M, Gaessler J, Zemann W, et al
    Diabetes Mellitus and Oral Cancer: A Retrospective Study from Austria.
    Anticancer Res. 2022;42:1899-1903.
    PubMed     Abstract available

  61. MAYO ZS, Ilori EO, Matia B, Smile TD, et al
    Limited Toxicity of Hypofractionated Intensity Modulated Radiation Therapy for Head and Neck Cancer.
    Anticancer Res. 2022;42:1845-1849.
    PubMed     Abstract available

  62. TSUTSUMI S, Momiyama K, Ichinoe M, Kato T, et al
    The Significance of CD109 Expression in Oropharyngeal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:2061-2070.
    PubMed     Abstract available

    March 2022
  63. SUZUKI H, Yokoi M, Hagiwara S, Sasaki E, et al
    A Case of Salvage Maxillectomy for Recurrent Oral Cancer After Boron Neutron Capture Therapy During the COVID-19 Pandemic.
    Anticancer Res. 2022;42:1653-1657.
    PubMed     Abstract available

  64. ITO T, Okamoto I, Tokashiki K, Sato H, et al
    PD-L1 Expression and Survival Rates Using TPS and CPS for Nivolumab-treated Head-and-Neck Cancer.
    Anticancer Res. 2022;42:1547-1554.
    PubMed     Abstract available

  65. OKADA T, Fushimi C, Matsuki T, Okamoto I, et al
    Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:1607-1613.
    PubMed     Abstract available

  66. OHSAWA M, Hamai Y, Emi M, Ibuki Y, et al
    Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma.
    Anticancer Res. 2022;42:1499-1507.
    PubMed     Abstract available

  67. LIU A, Borges PM, Tay YS, Thompson LDR, et al
    Thyroid Follicular Cell-derived Carcinomas in a Background of Multiple Adenomatous Nodules Leading to a Diagnosis of PTEN Hamartoma Tumor Syndrome in an Adult Patient With a Novel RECQL4 Mutation.
    Anticancer Res. 2022;42:1481-1485.
    PubMed     Abstract available

  68. CLAUSEN S, Falk M, Oesterling F, Fehr A, et al
    Outcome of Ordinary Polymorphous Adenocarcinomas of the Salivary Glands in Comparison With Papillary and Cribriform Subtypes.
    Anticancer Res. 2022;42:1455-1463.
    PubMed     Abstract available

  69. MUSHA A, Kubo N, Kawamura H, Okano N, et al
    Carbon-ion Radiotherapy for Inoperable Head and Neck Bone and Soft-tissue Sarcoma: Prospective Observational Study.
    Anticancer Res. 2022;42:1439-1446.
    PubMed     Abstract available

  70. JIN MC, Qian ZJ, Megwalu UC
    Risk of Second Primary Malignancies After External Beam Radiotherapy for Thyroid Cancer.
    Anticancer Res. 2022;42:1359-1365.
    PubMed     Abstract available

    February 2022
  71. URAKAWA N, Kanaji S, Suzuki S, Sawada R, et al
    Prognostic and Clinicopathological Significance of Lymph Node Metastasis in the Esophagogastric Junction Adenocarcinoma.
    Anticancer Res. 2022;42:1051-1057.
    PubMed     Abstract available

  72. HASHIMOTO K, Yasumatsu R, Kuga R, Hongo T, et al
    Treatment Efficacy of PD-1 Inhibitor Therapy in Patients With Recurrent and/or Metastatic Salivary Gland Carcinoma.
    Anticancer Res. 2022;42:981-989.
    PubMed     Abstract available

  73. DAVAKIS S, Charalabopoulos A, Kyros E, Sakarellos P, et al
    Minimally Invasive Transcervical Esophagectomy With Mediastinal Lymphadenectomy for Cancer. A Comparison With Standardized Techniques.
    Anticancer Res. 2022;42:675-680.
    PubMed     Abstract available

    January 2022
  74. RUDHART SA, Langen P, Thangavelu K, Gehrt F, et al
    Clinical Impact of CYFRA 21-1 a Marker for Treatment Failure in Patients With Oropharyngeal Cancer Treated by Radio(chemo)therapy.
    Anticancer Res. 2022;42:137-146.
    PubMed     Abstract available

  75. VEGH A, Banyai D, Ujpal M, Somogyi KS, et al
    Prevalence of Diabetes and Impaired Fasting Glycemia in Patients With Oral Cancer: A Retrospective Study in Hungary.
    Anticancer Res. 2022;42:109-113.
    PubMed     Abstract available

  76. ALSHARIF U, Steller D, Falougy M, Tharun L, et al
    The Benefit of Postoperative Radiotherapy and Extending Neck Dissection in pT1-2 Oral Squamous Cell Carcinoma With a Single Ipsilateral Cervical Lymph Node Metastasis (pN1).
    Anticancer Res. 2022;42:97-104.
    PubMed     Abstract available

  77. AL-JUMAYLI M, Choucair K, Al-Obaidi A, Park R, et al
    Pre-operative Carboplatin/Paclitaxel Versus 5-Fluorouracil (5-FU)-based Chemoradiotherapy for Older Adults With Esophageal Cancer.
    Anticancer Res. 2022;42:59-66.
    PubMed     Abstract available

  78. KONISHI M, Takeuchi Y, Kubo K, Imano N, et al
    Reirradiation Using (198)Au Grain Brachytherapy for Recurrent Oral Cancer Cases Previously Treated by Definitive Radiotherapy.
    Anticancer Res. 2022;42:293-300.
    PubMed     Abstract available

  79. YOSHIDA T, Nishino T, Goto M, Inoue S, et al
    ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
    Anticancer Res. 2022;42:195-203.
    PubMed     Abstract available

  80. KAMADA T, Ohdaira H, Ito E, Fuse Y, et al
    Preoperative Masseter Muscle Sarcopenia Predicts Mortality in Patients With Oesophageal Cancer.
    Anticancer Res. 2022;42:301-310.
    PubMed     Abstract available

  81. KONISHI M, Fujita M, Shimabukuro K, Wongratwanich P, et al
    Predictive Factors of Late Cervical Lymph Node Metastasis Using Intraoral Sonography in Patients With Tongue Cancer.
    Anticancer Res. 2022;42:287-292.
    PubMed     Abstract available

  82. TOYA R, Watakabe T, Murakami D, Matsuyama T, et al
    Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil for T3 N0 Glottic Carcinoma Without Vocal Cord Fixation.
    Anticancer Res. 2022;42:205-209.
    PubMed     Abstract available

    December 2021
  83. YOSHINO K, Okamoto I, Sato H, Okada T, et al
    Effect of Concomitant Lafutidine on Adjuvant S-1 for Head and Neck Cancer: A Comparative Study.
    Anticancer Res. 2021;41:6279-6285.
    PubMed     Abstract available

  84. HAMAI Y, Hihara J, Emi M, Ibuki Y, et al
    Prospective Randomized Trial of Early Postoperative Enteral and Total Parenteral Nutrition for Treating Esophageal Cancer.
    Anticancer Res. 2021;41:6237-6246.
    PubMed     Abstract available

  85. YOSHIMURA RI, Toda K, Watanabe H, Kaida A, et al
    Efficacy and Safety of Induction Chemotherapy and/or External Beam Radiotherapy Followed by Brachytherapy in Patients With Tongue Cancer.
    Anticancer Res. 2021;41:6259-6266.
    PubMed     Abstract available

  86. YUE CH, Chen CH, Pan YR, Chen YP, et al
    Cetyltrimethylammonium Bromide Disrupts Mesenchymal Characteristics of Human Tongue Squamous Cell Carcinoma SCC4 Cells Through Modulating Canonical TGF-beta/Smad/miR-181b/TIMP3 Signaling Pathway.
    Anticancer Res. 2021;41:6095-6104.
    PubMed     Abstract available

  87. NAKAMURA S, Mukudai Y, Chikuda J, Zhang M, et al
    Combinational Anti-tumor Effects of Chemicals from Paeonia lutea Leaf Extract in Oral Squamous Cell Carcinoma Cells.
    Anticancer Res. 2021;41:6077-6086.
    PubMed     Abstract available

  88. HARADA K, Ferdous T, Mishima K
    Efficacy of a Novel Oral Chemotherapeutic Agent, TAS-102, Against Human Oral Squamous Cell Carcinoma Cells.
    Anticancer Res. 2021;41:6039-6049.
    PubMed     Abstract available

    November 2021
  89. BABA D, Fushimi C, Hanyu K, Masubuchi T, et al
    Prognostic Factors of Potential Early Recurrence of Hypopharyngeal Carcinoma.
    Anticancer Res. 2021;41:5761-5766.
    PubMed     Abstract available

  90. WU J, Galvan KJ, Bogard RD, Peterson CE, et al
    DNA Double-strand Break Signaling Is a Therapeutic Target in Head and Neck Cancer.
    Anticancer Res. 2021;41:5393-5403.
    PubMed     Abstract available

  91. JOGIAT U, Grant C, Bedard ELR, Au K, et al
    Esophageal Adenocarcinoma Metastasizing to a Solitary Fibrous Tumor: An Unprecedented Case of Tumor-to-tumor Metastasis.
    Anticancer Res. 2021;41:5835-5838.
    PubMed     Abstract available

  92. NARUSE T, Yanamoto S, Otsuru M, Yamakawa N, et al
    Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5785-5791.
    PubMed     Abstract available

  93. NA YM, Cho JS, Park MH
    Levothyroxine Cessation After Thyroid Lobectomy for Papillary Thyroid Cancer Can Be Achieved at the Same Rate as that for Benign Tumors Regardless of the Duration of Thyroid-stimulating Hormone Suppression.
    Anticancer Res. 2021;41:5713-5721.
    PubMed     Abstract available

  94. ALSHARIF U, Hofmann M, Gebhard M, Tharun L, et al
    Double Positivity for HPV DNA/P16(INK4a) Does Not Influence Survival of Patients With Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5557-5568.
    PubMed     Abstract available

  95. CIERPIKOWSKI P, Lis-Nawara A, Bar J
    SHH Expression Is Significantly Associated With Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:5405-5413.
    PubMed     Abstract available

    October 2021
  96. HUANG YH, Hung YS, Lai CC, Ho MM, et al
    Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
    Anticancer Res. 2021;41:5213-5222.
    PubMed     Abstract available

  97. RADES D, Kopelke S, Soror T, Bartscht T, et al
    Risk Factors for Sleep Disturbances in Patients Scheduled for Radiotherapy of Head-and-Neck Cancer.
    Anticancer Res. 2021;41:5065-5069.
    PubMed     Abstract available

  98. IMAIZUMI T, Matsuda K, Tanaka K, Kondo H, et al
    Detection of Endogenous DNA Double-strand Breaks in Oral Squamous Epithelial Lesions by P53-binding Protein 1.
    Anticancer Res. 2021;41:4771-4779.
    PubMed     Abstract available

  99. EISMANN J, Elsayad K, Rolf D, Sarif I, et al
    Intensity-modulated Radiotherapy in Patients With Aggressive Extranodal Non-Hodgkin Lymphoma of the Head and Neck.
    Anticancer Res. 2021;41:5131-5135.
    PubMed     Abstract available

  100. LANDSTROM F, Aspenblad E, Reizenstein J, Kristiansson S, et al
    The Value of Post-treatment Surveillance for Detection of Loco-regional Recurrences in Oral Tongue Cancer.
    Anticancer Res. 2021;41:5059-5063.
    PubMed     Abstract available

  101. DOMB C, Smile TD, Reddy C, Woody NM, et al
    Updated Outcomes of Split Course Radiotherapy in Elderly or Infirm Patients With Advanced Cancers of the Head and Neck.
    Anticancer Res. 2021;41:4995-5000.
    PubMed     Abstract available

    September 2021
  102. SAKAI M, Sohda M, Uchida S, Yamaguchi A, et al
    Fibrin/fibrinogen Degradation Products Are Associated With Tumor Stage and Prognosis in Patients Undergoing Resection of Esophageal Cancer.
    Anticancer Res. 2021;41:4523-4527.
    PubMed     Abstract available

  103. KAWASAKI M, Sakabe T, Kodani I, Umekita Y, et al
    Cytoplasmic-only Expression of Maspin Predicts Poor Prognosis in Patients With Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:4563-4570.
    PubMed     Abstract available

  104. KOIKE K, Nishiyama K, Dehari H, Ogi K, et al
    Prognostic Value of CD45Ro(+) T-Cell Expression in Patients With Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:4515-4522.
    PubMed     Abstract available

    August 2021
  105. AGAWA K, Yamashita K, Nakagawa A, Yamada K, et al
    Simple Cancer Stem Cell Markers Predict Neoadjuvant Chemotherapy Resistance of Esophageal Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:4117-4126.
    PubMed     Abstract available

  106. TOKASHIKI K, Okamoto I, Okada T, Sato H, et al
    Postoperative Complications of Jejunal and Skin Valve Reconstruction in Free Reconstructive Surgery for Hypopharyngeal Carcinoma.
    Anticancer Res. 2021;41:4033-4038.
    PubMed     Abstract available

  107. LANDSTROM F, Kristiansson S, Reizenstein J
    The Role of Electrochemotherapy in Curative Treatment of Head and Neck Cancer and Advanced Skin Cancer: A Need for New Treatment Protocols?
    Anticancer Res. 2021;41:3977-3982.
    PubMed     Abstract available

  108. YAMASHITA K, Miyazaki Y, Nakatani D, Masuike Y, et al
    OSK-0028 in Patients With Esophageal Cancer Undergoing Esophagectomy: A Double-blind, Randomised Controlled Trial.
    Anticancer Res. 2021;41:3875-3884.
    PubMed     Abstract available

  109. DE OLIVEIRA NETO CP, Brito HO, DA Costa RMG, Brito LMO, et al
    Is There a Role for Sex Hormone Receptors in Head-and-neck Cancer? Links with HPV Infection and Prognosis.
    Anticancer Res. 2021;41:3707-3716.
    PubMed     Abstract available

  110. SAKAI M, Sohda M, Uchida S, Yamaguchi A, et al
    Combining Preoperative Immunoinflammatory Scores and (18)F-Fluorodeoxyglucose Positron-emission Tomography Predicts Beneficiaries of Salvage Esophagectomy.
    Anticancer Res. 2021;41:4005-4011.
    PubMed     Abstract available

  111. WU TK, Ou YC, Chen YP, Huang FM, et al
    Cetyltrimethylammonium Bromide Attenuates the Mesenchymal Characteristics of Hypopharyngeal Squamous Cell Carcinoma Through Inhibiting the EGFR/PI3K/AKT Signaling Pathway.
    Anticancer Res. 2021;41:3789-3799.
    PubMed     Abstract available

    July 2021
  112. CAO C, Poti SM, Ledgerwood LG, Lai J, et al
    Mixed HPV-related Neuroendocrine Carcinoma and HPV-related Squamous Cell Carcinoma of the Base of Tongue in a Patient With Incidental Identification of Synchronous Metastatic Papillary Thyroid Carcinoma.
    Anticancer Res. 2021;41:3639-3642.
    PubMed     Abstract available

  113. LANDSTROM F, Kristiansson S, Appelros P
    Neurological Complications After Electrochemotherapy Treatment in the Head and Neck Area.
    Anticancer Res. 2021;41:3519-3522.
    PubMed     Abstract available

  114. KNITTER S, Andreou A, Hofmann T, Chopra S, et al
    Minimally Invasive Versus Open Ivor-Lewis Esophagectomy for Esophageal Cancer or Cancer of the Gastroesophageal Junction: Comparison of Postoperative Outcomes and Long-term Survival Using Propensity Score Matching Analysis.
    Anticancer Res. 2021;41:3499-3510.
    PubMed     Abstract available

  115. LUNDIN E, Reizenstein J, Landstrom F, Bergqvist M, et al
    Radiotherapy as Elective Treatment of the Node-negative Neck in Oral Squamous Cell Cancer.
    Anticancer Res. 2021;41:3489-3498.
    PubMed     Abstract available

  116. FUJITA J, Nakajima M, Muroi H, Kikuchi M, et al
    The Prognostic Significance of Plakophilin-1 Expression in Esophageal Cancer.
    Anticancer Res. 2021;41:3401-3407.
    PubMed     Abstract available

  117. KII T, Sakuma K, Tanaka A
    PTEN Is Activated by the Addition of Cetuximab to Paclitaxel in Oral Squamous Cell Carcinoma.
    Anticancer Res. 2021;41:3363-3370.
    PubMed     Abstract available

  118. HYAKUSOKU H, Sawakuma K, Sano D, Takahashi H, et al
    FosL1 Regulates Regional Metastasis of Head and Neck Squamous Cell Carcinoma by Promoting Cell Migration, Invasion, and Proliferation.
    Anticancer Res. 2021;41:3317-3326.
    PubMed     Abstract available

    June 2021
  119. STAACKMANN C, Ribbat-Idel J, Perner S, Idel C, et al
    Palliative Local Radiotherapy for Advanced Squamous Cell Carcinoma of the Head-and-Neck: Prognostic Factors of Survival.
    Anticancer Res. 2021;41:3205-3210.
    PubMed     Abstract available

  120. HAMAI Y, Emi M, Ibuki Y, Kurokawa T, et al
    Comparison of Open and Thoracoscopic Esophagectomy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy.
    Anticancer Res. 2021;41:3011-3021.
    PubMed     Abstract available

  121. KYRODIMOS E, Chrysovergis A, Mastronikolis N, Tsiambas E, et al
    Impact of Topoisomerases Complex Deregulation on Head and Neck Carcinoma Genomic Instability.
    Anticancer Res. 2021;41:2773-2779.
    PubMed     Abstract available

  122. RADES D, Staackmann C, Ribbat-Idel J, Perner S, et al
    A New Survival Score for Patients Scheduled for Palliative Irradiation of Locally Advanced Carcinoma of the Head-and-Neck.
    Anticancer Res. 2021;41:3055-3058.
    PubMed     Abstract available

  123. SARMA D, Karna R, Nasrullah A, Zhang Q, et al
    Primary Esophageal Small Cell Carcinoma Masquerading as Non-Hodgkin Lymphoma in a Young Patient.
    Anticancer Res. 2021;41:3023-3027.
    PubMed     Abstract available

  124. OKUHATA K, Monzen H, Tamura M, Matsumoto K, et al
    Plan Complexity and Delivery Accuracy of Knowledge-based Volumetric Modulated Arc Therapy Plans with Single Optimization for Oropharyngeal Cancer.
    Anticancer Res. 2021;41:2925-2931.
    PubMed     Abstract available

    May 2021
  125. RADES D, Staackmann C, Schild SE
    Karnofsky Performance Score - An Independent Prognostic Factor of Survival After Palliative Irradiation for Sino-nasal Cancer.
    Anticancer Res. 2021;41:2495-2499.
    PubMed     Abstract available

  126. HAAG A, Huffman D, Peterson C, Shankar K, et al
    Cutaneous Lesion of the Nose as Initial Presentation of Esophageal Adenocarcinoma.
    Anticancer Res. 2021;41:2485-2488.
    PubMed     Abstract available

  127. IWASAKI T, Onda T, Honda H, Hayashi K, et al
    Over-expression of PDE5 in Oral Squamous Cell Carcinoma - Effect of Sildenafil Citrate.
    Anticancer Res. 2021;41:2297-2306.
    PubMed     Abstract available

    April 2021
  128. YU WN, Lin HF, Lee YI, Shia WC, et al
    PBK Expression Is Associated With Prognosis of Patients With Oral Squamous Cell Carcinoma Treated With Radiotherapy: A Retrospective Study.
    Anticancer Res. 2021;41:2177-2182.
    PubMed     Abstract available

  129. SAKAI M, Sohda M, Saito H, Nakazawa N, et al
    Concurrent Chemoradiotherapy With Docetaxel, Cisplatin, and 5-Fluorouracil (DCF-RT) vs. Cisplatin and 5-Fluorouracil (CF-RT) for Patients With Unresectable Locally Advanced Esophageal Cancer in a Real-world Clinical Setting.
    Anticancer Res. 2021;41:2141-2145.
    PubMed     Abstract available

  130. FRIEDRICH RE, Scheuer HT, Zustin J, Luebke AM, et al
    Microdont Developing Outside the Alveolar Process and Within Oral Diffuse and Plexiform Neurofibroma in Neurofibromatosis Type 1.
    Anticancer Res. 2021;41:2083-2092.
    PubMed     Abstract available

  131. SUZUKI M, Takenaka Y, Kishikawa T, Yamamoto Y, et al
    Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer.
    Anticancer Res. 2021;41:2045-2051.
    PubMed     Abstract available

  132. TAKAKUSAGI Y, Kusunoki T, Kano K, Anno W, et al
    Dosimetric Comparison of Radiation Therapy Using Hybrid-VMAT Technique for Stage I Esophageal Cancer.
    Anticancer Res. 2021;41:1951-1958.
    PubMed     Abstract available

  133. FUKUDA M, Ogasawara Y, Hayashi H, Okuyama A, et al
    Down-regulation of Glutathione Peroxidase 4 in Oral Cancer Inhibits Tumor Growth Through SREBP1 Signaling.
    Anticancer Res. 2021;41:1785-1792.
    PubMed     Abstract available

  134. PAWLICZAK J, Kolb M, Bauer M, Gminski R, et al
    Micronucleus Formation in Primary Oropharyngeal Epithelial Cells Reveals Mutagenicity of Cement Dusts.
    Anticancer Res. 2021;41:1849-1858.
    PubMed     Abstract available

  135. HOTTA H, Hamamura K, Shibuya H, Ohmi Y, et al
    Lewis y Expressed in Oral Squamous Cell Carcinoma Attenuates Malignant Properties via Down-regulation of EGF Signaling.
    Anticancer Res. 2021;41:1821-1830.
    PubMed     Abstract available

  136. OGO A, Miyake S, Kubota H, Higashida M, et al
    The Mechanism of the Synergistic Anticancer Effect of CDDP and EPA in the TE1 Cell Line.
    Anticancer Res. 2021;41:1771-1778.
    PubMed     Abstract available

  137. KOERDT S, Raguse JD, Neumann F, Beck-Broichsitter B, et al
    Value of Panendoscopy in the Identification of Synchronous Malignancies in Patients Suffering from Oral Squamous Cell Carcinoma Without Clinical Signs of a Second Primary Tumor.
    Anticancer Res. 2021;41:2039-2044.
    PubMed     Abstract available

    March 2021
  138. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available

  139. OWIN N, Elsayad K, Rolf D, Haverkamp U, et al
    Radiotherapy as Part of Treatment Strategies in Nasal Cavity and Paranasal Sinus Malignancies.
    Anticancer Res. 2021;41:1587-1592.
    PubMed     Abstract available

  140. KURIYAMA K, Sohda M, Watanabe T, Saito H, et al
    Resistance to Preoperative Oral Care Is Associated With Postoperative Pneumonia After Oesophageal Cancer Surgery.
    Anticancer Res. 2021;41:1507-1514.
    PubMed     Abstract available

  141. FRANZEN AM, Windfuhr JP
    Tonsillectomy as a Prevention Strategy in the Light of Increasing Incidence of Oropharyngeal Cancer - a Research of Current Literature.
    Anticancer Res. 2021;41:1157-1161.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.